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ABSTRACT
β2-chimaerin is a Rac1-specific negative regulator and a candidate tumor 
suppressor in breast cancer but its precise function in mammary tumorigenesis in vivo 
is unknown. Here, we study for the first time the role of β2-chimaerin in breast cancer 
using a mouse model and describe an unforeseen role for this protein in epithelial 
cell-cell adhesion. We demonstrate that expression of β2-chimaerin in breast cancer 
epithelial cells reduces E-cadherin protein levels, thus loosening cell-cell contacts. In 
vivo, genetic ablation of β2-chimaerin in the MMTV-Neu/ErbB2 mice accelerates tumor 
onset, but delays tumor progression. Finally, analysis of clinical databases revealed an 
inverse correlation between β2-chimaerin and E-cadherin gene expressions in Her2+ 
breast tumors. Furthermore, breast cancer patients with low β2-chimaerin expression 
have reduced relapse free survival but develop metastasis at similar times. Overall, 
our data redefine the role of β2-chimaerin as tumor suppressor and provide the first 
in vivo evidence of a dual function in breast cancer, suppressing tumor initiation but 
favoring tumor progression.
INTRODUCTION
Rac1 is a member of the Rho family of GTPases 
which regulates a variety of cellular processes including 
proliferation, survival, cell adhesion and motility [1]. 
Deregulation of such processes are hallmarks of cancer 
and not surprisingly, altered Rac1 activity has been 
associated with malignant transformation in various 
types of cancer including breast cancer [2–4]. Studies to 
determine the molecular mechanisms responsible for the 
hyperactivation of Rac1 in tumors unveiled that genetic 
alterations on this GTPase are very rare [5, 6]. Instead, 
deregulation of Rac1 typically occurs at the level of their 
regulatory proteins, the guanine nucleotide exchange 
factors (GEFs), the GDP dissociation inhibitors (GDIs), 
and the GTPase activating proteins (GAPs) [7–9].
β2-chimaerin is one of the few Rac-GAP proteins 
that have been implicated in breast cancer [7]. This 
protein is a product of the CHN2 gene which also 
encodes the testis-specific β1-chimaerin and a recently 
identified β3-chimaerin isoform [10, 11]. β2-chimaerin 
possesses three conserved structural domains; an SH2 
domain, a C1 domain that bind diacylglycerol (DAG), 
and a catalytic GAP domain with specificity for the Rac 
GTPase [12–14]. This combination of structural domains 
confers β2-chimaerin the property to regulate Rac 
activity via receptors coupled to DAG generation such 
as the epidermal growth factor (EGF) receptors [14, 15]. 
Deregulation of the CHN2 gene has been associated with 
human pathologies including mental disorders [16, 17], 
insulin resistance [18], and cancers such as glioblastoma, 
hepatosplenic T-cell lymphoma and breast cancer [19–21].
The evidences that link β2-chimaerin and breast 
cancer are very limited but suggest a tumor suppressor 
role for this protein. For example, downregulation of 
β2-chimaerin has been reported in human breast cancer 
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cell lines and in a few number of human breast cancer 
samples [20]. Conversely, restoration of β2-chimaerin in 
breast cancer cells inhibits proliferation, impairs migration 
and reduces the tumorigenic potential [20, 22–24]. The 
molecular mechanisms underlying these anti-tumorigenic 
effects of β2-chimaerin are only partially elucidated. The 
inhibition of Rac1 by β2-chimaerin reduces cyclin D1 
levels and pRb phosphorylation, thus impairing G1/S cell 
cycle progression [20]. Furthermore, inhibition of cell 
proliferation by β2-chimaerin is also observed in response 
to heregulin stimulation, ligands for the ErbB receptors 
that play important roles in breast tumorigenesis [24, 25]. 
How β2-chimaerin affects breast cancer cell migration and 
invasion is less studied, although it seems clear that its 
Rac1-specific GAP activity has a role in these processes 
by modulating actin dynamics [15, 22]. Interestingly, 
the ablation of the Drosophila orthologue of chimaerin 
produces aberrant cell contacts in the eye epithelium, 
suggesting a role for this protein in the regulation of cell-
cell adhesion [26].
The above studies suggest that β2-chimaerin can 
regulate various processes important in breast cancer 
development and progression, but the data so far are too 
limited to validate this protein as a target of therapeutic 
interest. In this study we have used a combination of in 
vitro analysis in breast cancer cell lines, a well-defined 
mouse model of breast cancer, and bioinformatics analyses 
of human breast cancer databases to delineate the role of 
β2-chimaerin in breast cancer.
RESULTS
β2-chimaerin alters E-cadherin expression in 
MCF7 breast cancer cells
β2-chimaerin has been proposed to influence 
cytoskeleton-mediated processes in different cell types by 
inhibiting Rac activity [15, 22, 27, 28], but these functions 
are only poorly characterized in breast cancer epithelial 
cells. To further investigate this issue, we analyzed the 
effect of the ectopic expression of β2-chimaerin in MCF7 
cells, a breast cancer epithelial cell line with undetectable 
levels of endogenous β2-chimaerin [20]. To this end, we 
generated a MCF7 cell line stably expressing EGFP-tagged 
β2-chimaerin. Quantitative real-time RT-PCR analysis 
revealed that these cells had ~10-fold increase over the 
endogenous β2-chimaerin mRNA levels in normal human 
breast tissue (Supplementary Figure S1). We corroborated 
that the expressed β2-chimaerin-EFGP was fully functional 
as determined by its ability to inhibit Rac activation by 
EGF or heregulin (HRG) as previously described [20, 
24] (Figure 1A). Since Rac1 activity is essential for the 
control of the actin cytoskeleton, cell-matrix adhesion 
and cell-cell adhesion, we examined the effects of β2-
chimaerin expression on these processes by staining the 
actin cytoskeleton as well as vinculin and E-cadherin, main 
components of focal adhesions and adherens junctions 
(AJs) respectively. Confocal immunofluorescence analysis 
revealed that cells expressing β2-chimaerin (MCF7-β2) 
retained the cobblestone morphology typical of epithelial 
cells and displayed the characteristic circumferential band 
of F-actin encircling the cells at the perijunctional level 
(Figure 1B). Notably, MCF7-β2 cells exhibited in average 
a larger cell size than control cells. The formation of focal 
adhesions, as measured by the appearance of vinculin 
clusters, was not affected by the expression of β2-chimaerin 
(Figure 1C). However, the E-cadherin signal at cell-cell 
contact was strongly reduced (Figure 1D). This effect is 
directly associated with the expression of β2-chimaerin, 
since silencing of this protein in the MCF7-β2 cells with a 
specific shRNA restored the normal levels of E-cadherin at 
the cell junctions (Figure 1E).
We next evaluated the expression of E-cadherin by 
Western blot analysis (Figure 2A). We found that cells 
expressing β2-chimaerin had a statistically significant 
reduction in the levels of E-cadherin compared to 
control cells. However, the expression of the AJ-
associated β-catenin and the tight junction (TJ) protein 
ZO-1 remained unchanged (Figure 2A). Similarly, 
immunofluorescence staining revealed that recruitment 
of β-catenin and ZO-1 to cell junctions was not severely 
compromised in MCF7-β2 cells (Fig 2B and 2C). These 
results suggest that β2-chimaerin predominantly alters 
E-cadherin expression but has no major effect on other AJ 
or TJ components.
β2-chimaerin regulates cell-cell adhesion and 
differentially affects migration and invasion 
depending on the cell context
E-cadherin is an important regulator of epithelial 
cell-cell adhesion by contributing to the formation and 
maintenance of adherens junctions (AJs) [29]. Because 
expression of β2-chimaerin reduced the levels of 
E-cadherin in MCF7 cells we first investigated whether 
β2-chimaerin influences AJs assembly. To this end, 
we conducted a calcium switch assay, which involves 
the disruption of E-cadherin-based cell-cell adhesion 
by removal of extracellular calcium, followed by the 
reassembly of cell-cell contacts after restoration of 
normal calcium levels [30]. We observed that, as expected, 
MCF7-β2 cells showed reduced levels of E-cadherin at 
AJs throughout junction formation. However, these cells 
formed apparently normal AJs after 2h of calcium repletion 
(Figure 3A). Furthermore, the remodeling of peripheral 
actin 2h after calcium restoration was not compromised 
and resulted in a similar extent of accumulation at cell-cell 
boundaries as in control cells.
We next performed a hanging drop assay that 
measures formation of junctions and their resistance to 
shearing force [31]. After 12 h of incubation of individual 
cells in hanging drops, both MCF7-control and MCF7-β2 
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Figure 1: The Rac-GAP β2-chimaerin alters E-cadherin in MCF7 cells. A. Active Rac1 in MCF7-control and MCF7-β2 cells 
after stimulation with EGF (100 ng/ml) or HRG (10 ng/ml). Densitometric analysis of Rac1-GTP levels normalized to the total Rac1 in 
two different experiments is shown in the histograms. Bars are the mean ± s.e.m. (*P < 0.05, ANOVA test). B. Immunofluorescence images 
of actin staining in MCF7-control and MCF7-β2 cells in confluent cultures. Note that cells expressing β2-chimaerin-EGFP have a bigger 
size. C. Immunostaining of vinculin in MCF7-control and MCF7-β2 cells grown on collagen IV-coated glasses. D. Immunostaining of 
E-cadherin in MCF7-control and MCF7-β2 cells. E. Immunostaining of E-cadherin in β2-chimaerin-silenced MCF7-β2 cells In B-E, panels 
show representative confocal immunofluorescence images from one of three independent experiments. Scale bars: 20 μm.
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Figure 2: β2-chimaerin regulates E-cadherin levels but has no effect on β-catenin and ZO-1. A. Western blot analysis 
of E-cadherin, β-catenin, and ZO-1 expression in MCF7-control and MCF7-β2 cells. Densitometric analysis normalized to the actin 
expression is shown in the histograms. Results are presented as means ± s.e.m. (n = 3) (*P < 0.05, unpaired two-tailed Student’s t-test). 
B-C. Immunofluorescence images of β-catenin and E-cadherin (B), or ZO-1 and E-cadherin (C), in MCF7-control and MCF7-β2 cells. 
Panels show representative confocal immunofluorescence images from one of three independent experiments. Scale bars: 20 μm.
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Figure 3: Expression of β2-chimaerin regulates cell-cell adhesion in MCF7 cells. A. Confocal immunofluorescence images 
of E-cadherin and actin staining of MCF7-control and MCF7-β2 cells subjected to a calcium switch assay. Panels show representative 
images from one of three independent experiments. Staining of cell grown in control media is also shown (upper panels). Scale bars: 40 
μm. B-C. Hanging drop aggregation assay in MCF7-control and MCF7-β2 cells (B) Representative images (4×) from each experimental 
condition (a higher magnification of cell aggregates after dissociation is shown in the inset) (C) Scatter plot of the size of aggregates from 
two independent experiments (***P < 0.001, unpaired two-tailed Student’s t-test).
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cells formed large interconnected clusters with a web-
like organization, but the aggregates of MCF7-β2 cells 
appeared much more loosely arranged and less compacted 
(Figure 3B). Upon trituration, aggregates dispersed 
into significantly smaller clusters in the β2-chimaerin 
expressing cells (Figure 3B, 3C). Together, these results 
indicate that β2-chimaerin does not impede the initial 
formation and the dynamics of AJ assembly but reduces 
the strength of cell-cell adhesion.
Given that a decrease of E-cadherin is associated 
with increased metastatic potential of tumor cells [32], 
our result showing that β2-chimaerin reduces E-cadherin 
is paradoxical, since it had been reported the inhibition 
of migration and invasion of breast cancer cells by β2-
chimaerin [22]. This discrepancy could be partially 
attributed to the use of non-epithelial breast cancer cells 
in the previous study. In order to clarify this issue, we 
compared the effect of β2-chimaerin in the migration and 
invasion of MCF7 and LM2 cells, a mesenchymal-like 
breast cancer cell line that lacks E-cadherin expression. 
To this end, we generated LM2 cells stably expressing 
β2-chimaerin fused to orange fluorescent protein 
(β2-chimaerin-OFP). Similar to MCF7-β2 cells, the 
expression of β2-chimaerin in LM2 cells was ~10-fold 
increase over the endogenous β2-chimaerin in normal 
human breast tissue (Supplementary Figure S1). By 
performing wound healing assays in these cell lines, 
we found that β2-chimaerin significantly inhibited cell 
migration in LM2 cells, while had no effect on MCF7 
cells (Figure 4A, 4B). Additionally, β2-chimaerin clearly 
reduced invasion of LM2 cells in transwell assays, 
whereas no invasion was observed in either MCF7-
control, or MCF7-β2 cells (Figure 4C).
Collectively, these results indicate that β2-
chimaerin regulates at least two different cytoskeleton-
dependent processes in breast cancer cells, migration and 
adhesion, but the final output of this regulation is highly 
dependent on the cell type. This raises an important 
question as for the exact role of β2-chimaerin in breast 
cancer, a pathology that arises from epithelial cells that 
switch to mesenchymal cells during cancer progression. 
To address this question we decided to study the role 
of β2-chimaerin in breast cancer development and 
progression in vivo.
Downregulation of β2-chimaerin in vivo 
accelerates tumor onset but delays tumor 
progression
In light of data reporting the downregulation 
of β2-chimaerin in breast cancer [20], and based on 
mechanistic insights showing that β2-chimaerin and 
Rac1 regulate cell proliferation, migration and invasion 
downstream of ErbB receptors [24, 33, 34], we selected 
the MMTV-Neu mouse model, which develops breast 
cancer due to overexpression of the Neu (ErbB2/Her2) 
receptor, to study the effects of β2-chimaerin deficiency 
in vivo. To corroborate that our studies in MCF7 cells 
showing that β2-chimaerin decreases E-cadherin can be 
extrapolated to this model, we first confirmed that β2-
chimaerin also downregulates E-cadherin protein levels 
in BT474 cells, a breast cancer epithelial cell line that 
overexpresses the ErbB2 receptor (Supplementary Figure 
S1 and S2).
To generate β2-chimaerin-deficient MMTV-Neu 
mice, we obtained mice with a gene-trap insertion in 
the Chn2 gene that eliminates β2-chimaerin expression 
(Supplementary Figure S3) and crossed them with 
MMTV-Neu mice to generate two cohorts of females; 
MMTV-Neu+/+/Chn2+/+ (thereafter named Neu/β2WT) 
and MMTV-Neu+/+/Chn2-/- (thereafter named Neu/
β2KO). Neu/β2KO females nursed their offsprings 
to maturity and showed no gross defects on the 
mammary gland architecture, suggesting that loss of 
β2-chimaerin does not impair mammary gland function 
(Supplementary Figures S3D and S4). Tumorigenesis 
studies revealed that mammary tumor development 
was significantly accelerated in Neu/β2KO mice as 
determined by Kaplan-Meier analysis (median time 
for tumor onset 8 months for Neu/β2KO mice versus 
11 months for Neu/β2WT mice, P < 0.0001) (Figure 
5A). Tumor incidence and tumor multiplicity did not 
show significant differences between both genotypes 
(Figure 5B and 5C), although tumor incidence was 
slightly higher in Neu/β2KO females (96.6% versus 
77.1%) (Figure 5B). Additionally, the mammary glands 
of Neu/β2KO females exhibited a significant increase 
in the number of preneoplastic lesions when compared 
with Neu/β2WT females (P < 0.05) (Figure 5D). These 
results indicate that more tumors are initiated in β2-
chimaerin-deficient mice during the time of primary 
tumor growth. Together, these data represent the first 
animal model that reveals a tumor suppressor role for 
β2-chimaerin in Her2/Neu induced primary mammary 
tumor formation, thus undoubtedly demonstrating a 
function for this protein in breast carcinogenesis.
We next evaluated whether there were differences 
in the metastatic potential between tumors that developed 
in Neu/β2WT and Neu/β2KO mice (Figure 5E-5H). 
We found no statistically significant difference in the 
incidence of lung metastasis or number of metastatic 
foci per mice between Neu/β2WT and Neu/β2KO 
mice (84.6% versus 64.7%, P = 0.24 and 23.6 ± 10.6 
versus 13.5 ± 5.0, P = 0.4 respectively) (Figure 5F and 
5G). Additionally, similar percentages of pulmonary 
metastasis were confined to the lung vasculature in mice 
of both genotypes (Figure 5H). Thus, despite previous 
studies in cell lines showing that β2-chimaerin inhibits 
processes involved in the metastatic cascade such as 
migration and invasion [22–24], our data demonstrate in 
vivo that downregulation of this protein does not result 
in increased metastasis.
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Figure 4: β2-chimaerin differentially affects cell migration and invasion in epithelial or mesenchymal-like cells. A-B. 
MCF7-control, MCF7-β2, LM2-control and LM2-β2 cell lines were subjected to a wound healing assay. A. Representative images showing 
the wound closure at two different time points. Nuclei were stained with Hoechst to corroborate that equal number of cells were used in 
each case. B. Quantification of the relative migration of control versus β2-chimaerin expressing cells. Results are presented as means ± 
s.e.m (n=7) (**P < 0.01, unpaired two-tailed Student’s t-test). C. Invasion of MCF7-control, MCF7-β2, and LM2-control and LM2-β2 cells 
was assessed using the Boyden chamber assay in the presence of Matrigel-coated filters. Images show crystal violet-stained migrated cells 
present at the lower face of the transwell membranes and are representative of one out of three different experiments.
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Deletion of β2-chimaerin in MMTV-Neu mice 
correlates with lower mammary tumor grade
To further evaluate the role of β2-chimaerin in 
tumor progression we compared the growth rates and 
tumor burden of Neu/β2WT and Neu/β2KO mammary 
tumors (Figure 6A and 6B). We found no statistically 
significant differences in these tumor features, although 
Neu/β2KO tumors showed a trend toward slower 
growth (P = 0.089) (Figure 6A). We next compared 
the histopathologic features of mammary tumors from 
both cohorts (Fig 6C and 6D). We found a significant 
Figure 5: β2-chimaerin deficiency accelerates mammary tumor onset but delays tumor progression in vivo. A. Kaplan-
Meier plots of tumor-free survival. Tumor latency was significantly reduced in Neu/β2KO mice (***P < 0.0001, log rank test). 
B. Mammary tumor incidence (P = 0.16). C. Scatter plot showing the number of mammary tumors per mouse (P = 0.95). D. Representative 
whole mounts of mammary glands showing preneoplastic lesions. Arrowheads: preneoplastic lesions. LN: lymphatic node. The number 
of preneoplasias per tumor-free mammary gland is shown in the histograms (*P < 0.05). E-H. Analysis of lung metastasis in Neu/β2WT 
and Neu/β2KO mice. (E) Representative H&E staining of lung sections showing metastasis. Top: arrowheads indicate metastatic foci in 
the lung (4×). Bottom: image showing metastasis invading the lung parenchyma (left) or inside a blood vessels (right) (20×). F.Incidence 
of lung metastasis (P = 0.24). G. Number of metastatic foci per mice (P = 0.397). H. Percentage of intravascular metastasis (P = 0.479). 
Statistical significance in B-D and F-H was assessed by Mann Whitney U-test. Results are presented as means ± s.e.m
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difference in tumor grade distribution among tumors 
from both genotypes (P = 0.015). 94.1% of the tumors 
from Neu/β2WT mice were poorly differentiated 
carcinomas with high histologic grade. However, 
in Neu/β2KO mice only 55.2% of the tumors were 
of high grade (Figure 6D). Additionally, large areas 
of necrosis and hemorrhage, which associates with 
tumor aggressiveness, were more frequently observed 
in tumors from control mice (88.2% in Neu/β2WT 
versus 43.5% in Neu/β2KO mice). Collectively, these 
data indicate that, despite the reduction in latency, 
tumors from Neu/β2KO mice exhibit a less aggressive 
behavior.
Deletion of β2-chimaerin in MMTV-Neu 
mice results in increased Rac activity without 
affecting proliferation, cell death or angiogenesis
To investigate the possible mechanisms by which 
β2-chimaerin ablation in MMTV-Neu mice influences 
breast tumor development and progression, we examined 
proliferation, cell death and angiogenesis by Ki-67, 
TUNEL and CD31 staining respectively. We found no 
statistically significant differences in these markers 
between tumors from Neu/β2WT and Neu/β2KO mice 
(Figure 7A). Additionally, Western blot analysis revealed 
no consistent differences in the activation or expression of 
Figure 6: β2-chimaerin deficiency correlates with lower mammary tumor grade. A. Tumor growth rate in Neu/β2WT and Neu/
β2KO mice. Tumor growth was analyzed for 6 weeks after tumor onset by weekly measurement of tumor volume. Data were represented 
on a semilogaritmic scale and fitted by linear regression. Slopes for each growth curve are represented (P = 0.089, Mann Whitney U-test). 
B. Tumor burden in Neu/β2WT and Neu/β2KO mice (P = 0.74, Mann Whitney U-test). C. Representative images of H&E staining of Neu/
β2WT and Neu/β2KO tumors (10×) showing poorly differentiated carcinomas (a, d), a moderately differentiated carcinoma (e), a tumor 
with hemorrhagic areas (b), and tumors with necrotic areas (c, f). D. Grade distribution of tumors according to the modified Elston and Ellis 
grading system (*P < 0.05, two tailed Fisher’s exact test).
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Figure 7: Deletion of β2-chimaerin in MMTV-Neu mice leads to Rac1 activation in tumors but has no effect in proliferation. 
A. Proliferation, apoptosis and angiogenesis in the tumors of the indicated genotypes. Representative images of Ki67, TUNEL and CD31 
staining are shown. Histograms show the percentage of Ki67-positive cells (P = 0.99, two tailed Fisher’s exact test), TUNEL-positive cells (P 
= 0.90, Mann Whitney U-test), and CD31-positive blood vessels (P = 0.469, Mann Whitney U-test). B. Western blot analysis of the expression 
and phosphorylation status of the indicated proteins in tumor lysates from mice of the indicated genotypes. Densitometric analyses are shown 
in the histograms. P-p38, pAKT and pERK levels were normalized to the corresponding total protein (P = 0.93, P = 0.92, and P = 0.83 
respectively, Mann Whitney U-test). Cyclin D1 protein level was normalized to actin (P = 0.78, Mann Whitney U-test). C. Rac1-GTP levels 
in mouse tumors from the indicated genotypes. A representative pull-down assay is shown. Histograms show the quantification of Rac1-GTP 
levels normalized to the total Rac1 (*P <0.05, Mann Whitney U-test). Results are presented as means ± s.e.m
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ERK, cyclin D1 or AKT, main signaling effectors activated 
by overexpression of Neu that drive cell proliferation 
and resistance to apoptosis [35–37] (Figure 7B). The 
phosphorylation status of the p38 MAP kinase, a regulator 
of cell death involved in mammary tumorigenesis [38] was 
also unaffected by β2-chimaerin ablation (Figure 7B).
β2-chimaerin functions are mediated through Rac 
inactivation [14, 20]. To corroborate that Rac activity 
was increased due to β2-chimaerin deletion and rule 
out compensatory effects by other GAP proteins, we 
performed Rac-GTP pull-down assays on tumor lysates 
from Neu/β2WT and Neu/β2KO mice. This analysis 
revealed a statistically significant increase in the levels of 
active Rac1 in Neu/β2KO tumors (P < 0.05) (Figure 7C). 
Together, these results suggest that loss of β2-chimaerin 
does not affect proliferative, apoptotic and angiogenic 
pathways in mammary tumors despite increasing Rac 
activity.
Loss of β2-chimaerin favors the maintenance of 
the epithelial state of breast tumors
Given that we found that expression of β2-chimaerin 
in breast cancer epithelial cells reduces E-cadherin, we 
asked whether ablation of β2-chimaerin in MMTV-
Neu mice could delay cancer progression by increasing 
E-cadherin levels. IHC analysis showed strong E-cadherin 
staining in tumors from both, Neu/β2WT and Neu/β2KO 
mice, which mainly localized to the cell-cell junctions 
(Figure 8A). Additionally, Western blot analysis showed 
similar E-cadherin content in tumors from both genotypes 
(Figure 8B). Similarly, the levels of the epithelial marker 
β-catenin were approximately equal in tumors from 
both cohorts (Figure 8B). We subsequently analyzed 
the expression of vimentin, a marker of epithelial-to-
mesenchymal transition (EMT), and found that more 
tumors from Neu/β2WT mice expressed this protein (8/11 
versus 4/12 in Neu/β2KO Figure 8B ). Similar results were 
observed at an earlier stage of breast tumor development 
(Figure 8C). Therefore, although the overall E-cadherin 
expression in MMTV-Neu mice tumors was not greatly 
affected by loss of β2-chimaerin, our data suggests that 
β2-chimaerin ablation favors the maintenance of the 
epithelial state of breast cancer cells, thus delaying EMT 
in MMTV-Neu tumors.
β2-chimaerin expression predicts relapse-free 
survival in human breast cancer and inversely 
correlates with E-cadherin expression in the 
Her2+ subtype
To evaluate the relevance of our experimental 
findings in the pathogenesis of human breast cancer, we 
first analyzed the expression levels of the β2-chimaerin 
and E-cadherin genes (CHN2 and CDH1 respectively) in 
Her2+ tumors and in normal breast tissue using microarray 
datasets that are publicly available. Given that recent 
studies suggests that Rac1 is involved in drug resistance 
in Her2+ patients [39, 40], only untreated patients were 
included in the study. We observed that CHN2 expression 
was reduced in Her2+ samples when compared with 
normal breast tissue, whereas the expression of CDH1 
was increased (Figure 9A). In a further analysis, we 
detected an inverse correlation between the expressions 
of both genes in Her2+ patients (Figure 9B). Next, we 
investigated whether β2-chimaerin expression correlates 
with survival. Using the SurvExpress tool to interrogate 
the TCGA (The Cancer Genome Atlas) database we 
found that CHN2 expression was significantly reduced 
in the high-risk population (Figure 9C). Additionally, 
we examined the prognostic value of CHN2 expression 
in a large clinical microarray database of human breast 
tumors [41]. We found that low CHN2 expression levels in 
unstratified breast cancer patients significantly correlated 
with reduced relapse-free survival (P < 0.001). However, 
distant-metastasis free survival was similar regardless of 
the levels of CHN2 expression (Figure 9D). Overall, these 
clinical data are in agreement with our results in Neu/
β2KO mice and support a tumor suppressor function of 
β2-chimaerin in tumor initiation.
DISCUSSION
Our study here unequivocally establishes for 
the first time the in vivo relevance of the Rac-GAP β2-
chimaerin in breast carcinogenesis. We found that, in 
agreement with its proposed role as tumor suppressor [20], 
deletion of β2-chimaerin in MMTV-Neu mice increases 
their susceptibility to develop breast tumors, as tumor 
latency was significantly reduced and mice had a higher 
incidence of preneoplasic lesions in the mammary glands. 
Unexpectedly, however, β2-chimaerin ablation delayed 
cancer progression since most tumors from β2-chimaerin 
KO mice were of lower grade.
Downregulation of β2-chimaerin has been shown to 
promote the proliferation in different epithelial cells [26, 
42]. Additionally, studies in breast cancer cells demonstrated 
that β2-chimaerin inhibits proliferation downstream of the 
ErbB2 receptors, an effect entirely dependent on its Rac-
GAP activity [20, 24, 25]. Therefore, we had hypothesized 
that deletion of β2-chimaerin would increase proliferation 
in Neu-induced tumors. However, our data revealed that 
tumors from β2-chimaerin KO mice had proliferation rates 
similar to those from control mice, despite having higher 
Rac1 activity. One possible explanation for this discrepancy 
lies in the different levels of expression of the upstream 
receptor in these experimental models. While the cell-
based studies were largely performed under conditions of 
normal growth factor signaling, the high overexpression of 
the ErbB2 receptor in tumors on the MMTV-Neu model is 
sufficient to strongly activate mitogenic signaling, and thus, 
may override β2-chimaerin deficiency (41).
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Figure 8: Deletion of β2-chimaerin in MMTV-Neu mice favors the maintenance of the epithelial state of breast tumors. 
A. Representative images of E-cadherin staining in tumors of the indicated genotypes collected after three months from tumor onset. B-
C. Western blot analysis of the expression of E-cadherin, β-catenin and vimentin in tumor lysates from Neu/β2WT and Neu/β2KO mice 
collected after 3 months from tumor onset (B) (same tumors as in Figure 6B), or after 1 month from tumor onset (C). Densitometric analysis 
of the expression of each protein normalized to actin expression is shown in the histograms. In B: P = 0.69 for E-cadherin, P = 0.87 for 
β-catenin and P = 0.17 for vimentin expression; in C: P = 0.81 for E-cadherin, P = 1.00 for β-catenin and P = 0.07 for vimentin (Mann 
Whitney U-test). Results are presented as means ± s.e.m.
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We have uncovered a new function of β2-chimaerin in 
the maintenance of cell junctions that may explain the delay 
in cancer progression in β2-chimaerin-deficient MMTV-
Neu mice by the impediment of the disassembly of cancer 
cells. This finding is supported by our results showing that 
expression of β2-chimaerin in MCF7 and BT474 cells 
reduces E-cadherin levels, resulting in the weakening of 
intercellular adhesive strength. Of note, our results parallel 
those found when Rac1 is inhibited in epithelial cells, which 
also induces the loss of E-cadherin at cell-cell contacts 
and diminishes contact strength [26, 30, 31, 43]. Besides, 
Rac1 inhibition results in larger cell diameters [43], an 
effect that we also observed in MCF7 cells expressing β2-
chimaerin and can be explained by a reduced tension due 
to the loosening of intercellular contacts [44]. Thus, our 
results are consistent with impairment on cell-cell adhesion 
by β2-chimaerin expression due to inhibition of Rac1. In 
support of this hypothesis, a previous study described that 
downregulation of the Drosophila chimaerin orthologue 
affects the stability of adherens junctions, an effect also 
attributed to increased activation of Rac in absence of 
chimaerin [26].
Figure 9: Reduced β2-chimaerin expression in human breast cancer inversely correlated with E-cadherin expression 
and is associated with reduced relapse-free survival. A. CHN2 and CDH1 expression values in normal breast tissue and untreated 
Her2+ breast tumors (data from the GSE29431 dataset). The P values shown were calculated by the Student’s t test followed by the 
Benjamini-Hochberg correction B. Inverse correlation between CHN2 and CDH1 expression in untreated Her2+ breast tumors. Data 
were retrieved from the GSE29431 and GSE65216 datasets and were plotted by expression value. Data analysis was performed using the 
Pearson’s correlation test. C. Association of β2-chimaerin expression with survival. Box plots were generated by SurvExpress and show 
the relative CHN2 mRNA expression levels of breast carcinoma samples from TCGA. Low- and high-risks groups are shown in green and 
black, respectively. The P value results from a Student’s t test analysis. D. Kaplan-Meier plots of relapse-free survival (RFS) and distant 
metastasis-free survival (DMFS) of breast cancer patients stratified by expression of the CHN2 gene; high (red) or low (black). Statistical 
significance was assessed by the log-rank test. **P < 0.01 for RFS analysis. In all studies the probe set for CHN2 was 213385_at and for 
CDH1 was 201130_s_at.
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Although reduction of E-cadherin leads to the 
acquisition of migratory and invasive properties of cancer 
cells, we have not observed any increase in the migration 
and the invasion of MCF7 cells expressing β2-chimaerin. 
This can be explained by the fact that cells still maintain 
a significant amount of E-cadherin and other components 
of AJs as well as TJs are unaffected. These results are in 
apparent contradiction with previous studies reporting 
the inhibition of migration and invasion of breast cancer 
cells by β2-chimaerin [22, 24]. These studies, however, 
were performed in non epithelial cells [22], or in MCF7 
cells subjected to chemotactic stimulus and experimental 
conditions that involve the disruption of cell–cell 
adhesion [24]. Furthermore, our results in mesenchymal 
breast cancer cells further corroborate that β2-chimaerin 
can inhibit migration and invasion in a non-epithelial 
context. Hence, our data, together with those of previous 
studies, suggest a differential role for β2-chimaerin in cell 
migration and invasion depending on the cell type and the 
cellular context.
Breast cancer is a pathology that originates 
from epithelial cells which acquire a mesenchymal 
phenotype during cancer progression. Considering the 
above results, loss of β2-chimaerin could either favor 
or delay the metastatic potential of breast cancer cells 
depending on their phenotype. Our in vivo analysis 
revealed that, indeed, ablation of β2-chimaerin hinders 
tumor progression. We observed a clear delay in the 
EMT in absence of β2-chimaerin, since significantly 
less Neu-induced tumors from β2-chimaerin KO 
mice showed expression of the mesenchymal marker 
vimentin, while most of the control mice expressed 
this marker. We could not establish a clear correlation 
between β2-chimaerin and E-cadherin expression in 
our in vivo model, as we observed in breast cancer 
cell lines, since tumors from both mice cohorts 
showed high levels of E-cadherin. Nevertheless, since 
changes in E-cadherin expression during metastatic 
progression are transient and confined to the invasive 
tumor front [45], we cannot rule out differences in 
this protein that we have not detected in our analysis. 
Importantly, the bioinformatics analyses of human 
breast cancer databases show an inverse correlation 
between E-cadherin and β2-chimaerin expression, 
which supports a role of β2-chimaerin in the regulation 
of E-cadherin in vivo. Interestingly, times to relapse are 
shorter in breast cancer patients with low β2-chimaerin 
expression than in patients with high expression but 
both groups of patients develop metastasis at similar 
times, suggesting that loss of β2-chimaerin may also 
delay metastasis in human breast cancer.
In summary, this study delineates for the first time 
the in vivo function of β2-chimaerin in breast cancer and 
provides further insight into the mechanisms by which this 
protein influences tumor progression.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance 
with the ethical standards, according to the Declaration 
of Helsinki and according to national and international 
guidelines. Animal care and work protocols were 
approved by the Bioethics Committees of the University 
of Valladolid and CSIC.
Cell lines
MCF7 and BT474 cells were provided by Dr. 
Pandiella (CIC, Salamanca, Spain) who authenticated 
the cells. The MDA-LM2-4175 (LM2) cell line was 
donated by Dr. Massagué (Memorial Sloan-Kettering 
Cancer Center, NY, USA). Cells were grown at 37°C and 
5% CO2 in DMEM supplemented with 10% fetal bovine 
serum (FBS), 1% L-glutamine and 100 units/ml penicillin 
and streptomycin (Gibco). MCF7 and BT474 cells stably 
expressing β2-chimaerin were generated by transfection 
of the pEGFP-N1-CHN2 vector encoding EGFP-tagged 
β2-chimaerin. The LM2 cell line contains a GFP reporter, 
and thus, to generate LM2 cells stably expressing β2-
chimaerin cells were transfected with a vector encoding 
Orange-fluorescent-protein-tagged β2-chimaerin (pOFP-
N1-CHN2). 48 h post-transfection, cells were selected 
with 500 μg/ml geneticin (Gibco), and then sorted by 
FACS to collect fluorescent cells expressing β2-chimaerin 
(MCF7-β2, BT474-β2 and LM2-β2). Non-fluorescent cells 
were also collected and used as control (MCF7-control, 
BT474-control and LM2-control).
To knock-down β2-chimaerin expression, MCF7-β2 
cells were infected with lentiviral shRNA targeting the β2-
chimaerin sequence (CGTACACAAACAGTGTTCCAA) 
or scrambled shRNA as control. After selection in 2 μg/
ml puromycin, EGFP-β2-chimaerin knock-down was 
confirmed by loss of GFP fluorescence in resistant cells.
Quantitative RT-PCR
Quantitative RT-PCR analysis was performed 
with the QuantiTect One step SYBR Green PCR Kit 
(Qiagen), using 150 ng of total RNA from the cell lines 
(isolated with TRIzol, Invitrogen) and from human 
breast tissue (Agilent). Primers for β2-chimaerin were: 
5′-GCAGGCGGATGAGCTTCTT-3′ (forward) and 
5′-CTCACCCACAAAGTGTTTCCC-3′ (reverse). Primers 
for GAPDH were: 5′-TGCACCACCAACTGCTTAG-3′ 
(forward) and 5′-GGATGCAGGGATGATGTTC-3′ 
(reverse). Quantitative RT-PCR was performed on a Light 
Cycler® 480 Real-Time PCR System (Roche Diagnostics). 
Relative β2-chimaerin expression was calculated using a 
standard 2−ΔΔCTmethod.
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Immunofluorescence
For E-cadherin, β-catenin, ZO-1 and actin staining, 
equal number of MCF7-β2 and MCF-7 cells were seeded 
on coverslips and grown to confluence. Cells were fixed 
with 3.7% formaldehyde, permeabilized in 0.2% Triton 
X-100 for 10 min and incubated in blocking solution 
containing 1% BSA and 100 mM glycine in phosphate-
buffered saline (PBS). Cells were then labelled with the 
following primary antibodies: anti-E-cadherin (610181, 
BD Transduction Laboratories), anti β-catenin (D10A8, 
Cell Signaling) or anti ZO-1 (D7D12, Cell Signaling). 
Actin was labelled with Alexa-647 phalloidin (Cell 
Signaling) or rhodamine-phalloidin (Invitrogen). For 
vinculin staining cells were seeded onto coverslips coated 
with collagen IV (30μg/ml), processed as indicated above 
and stained with anti-vinculin (V9264, Sigma). Nuclei 
were stained with DAPI (1μg/ml). Cells were imaged 
using a laser scanning confocal microscope (Leica 
TCS SP5 or Olympus Fluoview 1000) and confocal 
micrographs were processed with ImageJ (NIH).
Cell-cell adhesion assays
For calcium switch experiments, cells were 
incubated overnight in calcium-free DMEM (PAN 
Biotech) and then switched back to standard DMEM 
growth media. Cells were fixed at the indicated times, 
processed for E-cadherin and actin staining as indicated 
above and analyzed by confocal microscopy. Hanging 
drop aggregation assays were performed as described 
previously [31]. In brief, MCF7-β2 and MCF7-control 
cells were trypsinized, centrifuged, and resuspended as 
single-cell suspensions at 2 × 105 cells/ml. 30 µl drops of 
cell suspension were pipetted into the inside surfaces of 
10 cm culture dish lids. After overnight incubation, cells 
were subjected to shear force by passing them 10 times 
through a standard pipet tip. Cells were photographed 
using a microscope (Nikon Eclipse TS100) equipped with 
a digital camera (Nikon DS-5M). Cell cluster sizes were 
analyzed using ImageJ.
Migration and invasion assays
Cell migration was analyzed in wound healing 
assay. To this end, 2 × 105 control and β2-chimaerin 
expressing MCF7 or LM2 cells were seeded in 24-well 
plates. When cultures reached confluency, wounds were 
created by scraping with 200-μl plastic tips across the cell 
monolayer. The cell culture medium was then removed, 
wells were washed with PBS to remove detached cells and 
then 1 ml of DMEM media without serum was added to 
each well. Wound closure was monitored with a confocal 
microscope (Olympus Fluoview 1000) and images were 
captured every 5 min with a 10x objective. The wound 
healing rate was calculated using ImageJ.
Invasion assays were performed using 8-μm 
pore invasion chambers (Costar) that were coated with 
100 μl Matrigel (BD Biosciences) in DMEM (1:20). 
Control and β2-chimaerin expressing MCF7 and LM2 
cells were trypsinized, suspended in DMEM and plated 
in the upper chamber (2.5 × 105 cells/well). The lower 
chamber was filled with DMEM containing 10% FBS as 
chemoattractant. After 18-30 h incubation, the wells were 
washed with PBS and invasive cells located on the lower 
side of the chamber were stained with crystal violet, air-
dried and photographed.
Mice strains
All mice were housed at the Animal Research 
Facility of the University of Salamanca and the University 
of Valladolid. Mice containing a gene-trap insertion 
in the β2-chimaerin gene (Chn2) were obtained from 
Lexicon Genetics (Woodland, TX, USA) and were on 
a mixed C57Bl/6/129/SvEvBrd background. The gene 
trap was inserted in the intron 1 of the Chn2 gene that 
truncates the β2-chimaerin transcript immediately after 
the first coding exon. The gene trap does not affect the 
β1-chimaerin transcript which initiates from a promoter 
located upstream of exon 7. Genotyping was performed 
by PCR of mouse tail DNA according to Lexicon′s 
recommendations. Expression of β2- and β1-chimaerin 
transcripts were analyzed by RT-PCR using the following 
primers: 5′-CGTGGAAGGTGCCTACATCC-3′ (forward) 
and 5′-TTCACCATCTCTGTCAAACGCC-3′ (reverse) 
for amplification of β2-chimaerin, and 5′-GCTATGGTT 
CGGAAGTCCAAGC-3′ (forward) and 5′-TTCACCATCT 
CTGTCAAACGCC-3′ (reverse) for amplification of 
β1-chimaerin. The p36b4 with gene was used as 
control and was amplified with the following oligos: 
5′-GTGTTTGACAACGGCAGCATT-3′ (forward) and 
5′-TTGATGATGGAGTGT GGCACC-3′ reverse).
FVB/N-Tg (MMTV-Neu) 202Mul/J mice, which 
are FVB mice carrying the ErbB2 protooncogene under 
the control of the MMTV 3′promoter [46], were originally 
from the Jackson Laboratory (Bar Harbor, ME, USA). To 
generate β2-chimaerin-defficient MMTV-Neu mice, β2-
chimaerin KO mice (Chn2-/-) were first backcrossed to the 
FVB background for 4 generations. Homozygous Chn2-
/- mice were crossed with MMTV-Neu mice to generate 
double heterozygous mice that were then intercrossed to 
generate two cohorts of females; MMTV-Neu+/+/Chn2+/+ 
and MMTV-Neu+/+/Chn2-/-. All genotypes were confirmed 
by PCR of mouse tail DNA at time of killing.
Tumorigenesis analysis
MMTV-Neu+/+/Chn2+/+ and MMTV-Neu+/+/Chn2-/- 
virgin females were monitored twice weekly for tumor 
development. Once detected, tumors were measured 
weekly with a digital caliper. Total tumor volume was 
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calculated using the equation: volume = a × b2/2 where 
a is the longest dimension and b is the shortest. Animals 
were sacrificed 3 months after detection of the tumor 
unless the longest dimension of the largest tumor exceeded 
2.5 cm, or if mice exhibited signs of illness. At necropsy, 
mammary tumors were collected, fixed in 4% buffered 
formaldehyde or snap-frozen in liquid nitrogen. Whole 
mounts of the remaining mammary glands from tumor-
bearing mice were prepared as described below to quantify 
premalignant lesions. Tumor incidence was defined 
as the proportion of females that generated at least one 
mammary tumor during the experiment. Tumor growth 
was calculated by representing total tumor volume on a 
semilogaritmic scale and fitting by linear regression to 
calculate the slopes for each growth curve. Tumor burden 
was evaluated by assessing the total tumor volume per 
mouse.
For analysis of metastasis, lungs were collected, 
fixed in 4% buffered formaldehyde, and included in 
paraffin. The entire lungs were sectioned at 100 μm 
intervals, stained with H&E and scored for metastatic 
lesions.
Mammary gland whole mounts analysis
Whole mounts of the mammary glands were 
prepared as previously described [47] and photographed 
using a stereomicroscope (Leica EZ4HD). Images were 
analyzed using ImageJ software. The mammary gland 
length was measured from the nipple area to the end of the 
longest duct. The number of terminal end buds (TEBs) was 
counted under the stereomicroscope at 8× magnification.
Histological analysis and immunohistochemistry
Tumor specimens were paraffin-embedded, 
sectioned, and analyzed by H&E staining. Tumors were 
graded according to the modified Elston and Ellis grading 
system [48]. Immunohistochemistry was performed by 
independent personnel at the Histopathology units of 
either the CNIO (Madrid, Spain) or CIC (Salamanca, 
Spain). Proliferation and angiogenesis were monitored 
by immunohistochemical staining with antibodies against 
Ki67 (IR626, DAKO) and CD31 (IR610/IS610, DAKO), 
respectively. Apoptotic cells were detected using TUNEL 
labelling. E-cadherin staining was performed using anti 
E-cadherin (IR059) (DAKO). Images were acquired using 
a Nikon Eclipse 90i microscope.
Western blot assay
Protein lysates from cells lines were prepared in 
a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 1% Triton X-100, 0.2% DOC, 2mM EDTA, 
1 mM Na
3
VO4, 1 mM DTT, 50 mM NaF, and a mixture 
of protease inhibitors (Cømplete, Roche Molecular 
Biochemicals). To prepare protein lysates from tumors, 
frozen tumor samples were homogenized using a polytron 
(Ultra Turrax) in the buffer lysis described above (1:10 
w/v). Equivalent amounts of protein were resolved by 
SDS-PAGE and processed by immunoblotting analysis. 
The following primary antibodies were used: antibodies 
against E-cadherin (610181), β-catenin (D10A8), ZO-1 
(D7D12), vimentin (D21H3), p-ERK (9101), ERK (9102), 
p-AKT (Ser473) (4060), AKT (9272) and p-p38 (Thr180/
Tyr182) (9211) (Cell Signaling); cyclin D1 (sc-717) 
and p38 (sc-535) (Santa Cruz); Actin (A4700) and β2-
chimaerin (HPA018989) (Sigma) and GFP (MMs-118P) 
(Covance). Immunoblot–derived signals were quantified 
using Quantity One-1D.
Rac activation assay
Rac-GTP levels in cell lines and tumors were 
assessed by pull-down assay with a GST fusion protein 
containing the Rac1 binding domain of PAK1 (GST-
PBD) as described previously [14]. Briefly, MCF7 cell 
lines were seeded in six well plates, serum starved for 
48h and then stimulated with EGF (100 ng/ml) for 5 min 
or HRG (10 ng/ml) for 10 min. After stimulation cells 
were lysed in 400 μl of lysis buffer containing 20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 0.5% 
Igepal, 5 mM β-glycerophosphate, 1 mM DTT, 1 mM 
Na
3
VO4, 50 mM NaF, protease inhibitors (Cømplete, 
Roche Diagnostics), and 10 μg/sample of GST-PBD. 
Tumors were homogenized in the same lysis buffer (1:10 
w/v) without GST-PBD, precleared by centrifugation at 
14,000 rpm for 10 min at 4 °C and then, 10 μg of GST-
PBD was added to 1 ml of supernatant. Tumor and cell 
lysates were incubated with glutathione-Sepharose beads 
(GE Healthcare) for 1 h at 4 °C. After incubation, samples 
were extensively washed, boiled in SDS-PAGE sample 
buffer and separated by electrophoresis. Bound Rac1 
proteins were detected by immunoblotting using anti-Rac 
antibody (610651, BD transduction laboratories). Rac-
GTP levels were quantitated using the Quantity One 1D 
image analysis software (Bio-Rad).
Clinical dataset analysis
Gene expression analysis from GEO and TCGA 
databases were performed at the Bioinformatics Service 
at the University of Salamanca (Spain). CHN2 and CDH1 
gene expression were retrieved from GEO databases 
containing normalized microarray data from normal 
breast and untreated Her2+ breast cancer samples (datasets 
GSE29431 and GSE65216). Differences in expression 
between normal breast and Her2+ samples were 
assessed by Student’s t test followed by the Benjamini-
Hochberg correction. The correlation between CHN2 
and CDH1 expression in Her2+ patients was assessed 
using Pearson’s correlation test. The SurvExpress tool 
was used to interrogate the prognostic value of CHN2 
mRNA expression in TCGA database [49]. The P value 
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derived from a Student’s t test analysis. The effect of 
CHN2 expression on relapse-free survival and metastasis-
free survival in unstratified breast cancer patients was 
evaluated using the online tool Kaplan-Meier Plotter and 
the log-rank test based on the updated 2014 version [41]. 
In all studies the probe set for CHN2 was 213385_at, and 
for CDH1 201130_s_at.
Statistical analyses
Tumor latency in Neu/β2WT and Neu/β2KO mice 
was compared using the Kaplan–Meier estimator and 
the log-rank test. Fisher’s exact test was used to evaluate 
differences in grade distribution of tumors. Other analyses 
were performed with unpaired two-tailed Student’s t-test, 
Mann-Whitney U-test or one way ANOVA.
ACKNOWLEDGMENTS
We thank Carolin Barth, Rebecca Eccles and Paul 
Markus Müller (Max Delbrück Center for Molecular 
Medicine) for excellent technical assistance. We also 
thank Dr. Jesús Pérez-Losada, Dra. Carmen Guerrero, 
and Dra. Marina Holgado-Madruga (University of 
Salamanca, Spain), and Dr. Marcelo Kazanietz (University 
of Pennsylvania, USA) for useful comments about the 
manuscript.
FUNDING
This work was initially supported by a grant from 
the Spanish Ministry of Economy and Competitiveness 
to MJC (BFU2009-08051), but could be finished only 
thanks to the support from the Castilla-León Autonomous 
Government to MJC (grants BIO103/VA44/11, BIO/
VA22/14, CSI090U14 and BIO/VA34/15).
CONFLICTS OF INTEREST
The authors declare no conflict of interest.
REFERENCES
1. Etienne-Manneville S and Hall A. Rho GTPases in cell 
biology. Nature. 2002; 420:629-635.
2. Tang Y, Olufemi L, Wang MT and Nie D. Role of Rho 
GTPases in breast cancer. Front Biosci. 2008; 13:759-776.
3. Ellenbroek S and Collard J. Rho GTPases: functions 
and association with cancer. Clin Exp Metastasis. 2007; 
24:657-672.
4. Katz E, Sims AH, Sproul D, Caldwell H, Dixon MJ, 
Meehan RR and Harrison DJ. Targeting of Rac GTPases 
blocks the spread of intact human breast cancer. Oncotarget. 
2012; 3:608-619.
5. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, 
Graeff H, Harbeck N, Schmitt M and Lengyel E. Rac1 in 
human breast cancer: overexpression, mutation analysis, 
and characterization of a new isoform, Rac1b. Oncogene. 
2000; 19:3013-3020.
6. Kawazu M, Ueno T, Kontani K, Ogita Y, Ando M, 
Fukumura K, Yamato A, Soda M, Takeuchi K, Miki Y, 
Yamaguchi H, Yasuda T, Naoe T, Yamashita Y, Katada T, 
Choi YL, et al. Transforming mutations of RAC guanosine 
triphosphatases in human cancers. Proc Natl Acad Sci USA. 
2013; 110:3029-3034.
7. Wertheimer E, Gutierrez-Uzquiza A, Rosemblit C, Lopez-
Haber C, Sosa MS and Kazanietz MG. Rac signaling in 
breast cancer: a tale of GEFs and GAPs. Cell Signal. 2012; 
24:353-362.
8. Barrio-Real L and Kazanietz MG. Rho GEFs and cancer: 
linking gene expression and metastatic dissemination. Sci 
Signal. 2012; 5:pe43.
9. Bozza WP, Zhang Y, Hallett K, Rivera Rosado LA 
and Zhang B. RhoGDI deficiency induces constitutive 
activation of Rho GTPases and COX-2 pathways in 
association with breast cancer progression. Oncotarget. 
2015; 6:32723-32736.
10. Leung T, How BE, Manser E and Lim L. Germ cell beta-
chimaerin, a new GTPase-activating protein for p21rac, is 
specifically expressed during the acrosomal assembly stage 
in rat testis. J Biol Chem. 1993; 268:3813-3816.
11. Zubeldia-Brenner L, Gutierrez-Uzquiza A, Barrio-Real L, 
Wang H, Kazanietz MG and Leskow FC. β3-chimaerin, a 
novel member of the chimaerin Rac-GAP family. Mol Biol 
Rep. 2014; 41:2067-2076.
12. Leung T, How BE, Manser E and Lim L. Cerebellar 
β2-chimaerin, a GTPase-activating protein for p21 ras-
related rac is specifically expressed in granule cells and 
has a unique N-terminal SH2 domain. J Biol Chem. 1994; 
269:12888-12892.
13. Caloca MJ, Garcia-Bermejo ML, Blumberg PM, Lewin 
NE, Kremmer E, Mischak H, Wang S, Nacro K, Bienfait B, 
Marquez VE and Kazanietz MG. β2-chimaerin is a novel 
target for diacylglycerol: binding properties and changes in 
subcellular localization mediated by ligand binding to its C1 
domain. Proc Natl Acad Sci USA. 1999; 96:11854-11859.
14. Caloca MJ, Wang H and Kazanietz MG. Characterization 
of the Rac-GAP (Rac-GTPase-activating protein) activity 
of β2-chimaerin, a ’non-protein kinase C’ phorbol ester 
receptor. Biochem J. 2003; 375:313-321.
15. Wang H, Yang C, Leskow FC, Sun J, Canagarajah 
B, Hurley JH and Kazanietz MG. Phospholipase Cγ/
diacylglycerol-dependent activation of β2-chimaerin 
restricts EGF-induced Rac signaling. Embo J. 2006; 
25:2062-2074.
16. Barrio-Real L, Barrueco M, González-Sarmiento R and 
Caloca MJ. Association of a novel polymorphism of the 
Oncotarget18www.impactjournals.com/oncotarget
β2-Chimaerin gene (CHN2) with smoking. J Invest Med. 
2013; 61:1129-1131.
17. Hashimoto R, Yoshida M, Kunugi H, Ozaki N, Yamanouchi 
Y, Iwata N, Suzuki T, Kitajima T, Tatsumi M and Kamijima 
K. A missense polymorphism (H204R) of a Rho GTPase-
activating protein, the chimerin 2 gene, is associated with 
schizophrenia in men. Schizophr Res. 2005; 73:383-385.
18. Suliman SG, Stanik J, McCulloch LJ, Wilson N, Edghill 
EL, Misovicova N, Gasperikova D, Sandrikova V, Elliott 
KS, Barak L, Ellard S, Volpi EV, Klimes I et al. Severe 
insulin resistance and intrauterine growth deficiency 
associated with haploinsufficiency for INSR and CHN2: 
new insights into synergistic pathways involved in growth 
and metabolism. Diabetes. 2009; 58:2954-2961.
19. Yuan S, Miller DW, Barnett GH, Hahn JF and Williams BR. 
Identification and characterization of human β2-chimaerin: 
association with malignant transformation in astrocytoma. 
Cancer Res. 1995; 55:3456-3461.
20. Yang C, Liu Y, Leskow FC, Weaver VM and Kazanietz 
MG. Rac-GAP-dependent Inhibition of Breast Cancer 
Cell Proliferation by β2-Chimerin. J Biol Chem. 2005; 
280:24363-24370.
21. Finalet Ferreiro J, Rouhigharabaei L, Urbankova H, 
van der Krogt J-A, Michaux L, Shetty S, Krenacs L, 
Tousseyn T, De Paepe P, Uyttebroeck A, Verhoef G, 
Taghon T, Vandenberghe P, et al. Integrative genomic 
and transcriptomic analysis identified candidate genes 
implicated in the pathogenesis of hepatosplenic T-Cell 
lymphoma. PLoS one. 2014; 9:e102977.
22. Menna PL, Skilton G, Leskow FC, Alonso DF, Gomez 
DE and Kazanietz MG. Inhibition of aggressiveness 
of metastatic mouse mammary carcinoma cells by 
the β2-chimaerin GAP domain. Cancer Res. 2003; 
63:2284-2291.
23. Menna PL, Peche LY, Alonso DF and Gomez DE. Role 
of β2-chimaerin in the behaviour of murine mammary 
carcinoma cells in response to extracellular matrix 
components. Int J Mol Med. 2005; 15:91-95.
24. Yang C, Liu Y, Lemmon MA and Kazanietz MG. Essential 
role for Rac in heregulin beta1 mitogenic signaling: a 
mechanism that involves epidermal growth factor receptor 
and is independent of ErbB4. Mol Cell Biol. 2006; 
26:831-842.
25. Yang C, Klein E, Assoian R and Kazanietz M. Heregulin 
beta1 promotes breast cancer cell proliferation through 
Rac/ERK-dependent induction of cyclin D1 and p21Cip1. 
Biochem J. 2008; 410:167-175.
26. Bruinsma SP, Cagan RL and Baranski TJ. Chimaerin and 
Rac regulate cell number, adherens junctions, and ERK 
MAP kinase signaling in the Drosophila eye. Proc Natl 
Acad Sci USA. 2007; 104:7098-7103
27. Siliceo M, Garcia-Bernal D, Carrasco S, Diaz-Flores 
E, Leskow FC, Teixido J, Kazanietz MG and Merida 
I. β2-chimaerin provides a diacylglycerol-dependent 
mechanism for regulation of adhesion and chemotaxis of T 
cells. J Cell Sci. 2006; 119:141-152.
28. Caloca MJ, Delgado P, Alarcón B and Bustelo XR. Role 
of chimaerins, a group of Rac-specific GTPase activating 
proteins, in T-cell receptor signaling. Cell Signal. 2008; 
20:758-770.
29. Braga VMM. Cell–cell adhesion and signalling. Curr Opin 
Cell Biol. 2002; 14:546-556.
30. Braga VMM, Machesky LM, Hall A and Hotchin NA. 
The small GTPases Rho and Rac are required for the 
establishment of cadherin-dependent cell–cell contacts. 
J Cell Biol. 1997; 137:1421-1431.
31. Ehrlich JS, Hansen MDH and Nelson WJ. Spatio-temporal 
regulation of Rac1 localization and lamellipodia dynamics 
during epithelial cell-cell adhesion. Dev Cell. 2002; 
3:259-270.
32. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and 
Weinberg RA. Loss of E-cadherin promotes metastasis via 
multiple downstream transcriptional pathways. Cancer Res. 
2008; 68:3645-3654.
33. Fournier AK, Campbell LE, Castagnino P, Liu WF, 
Chung BM, Weaver VM, Chen CS and Assoian RK. 
Rac-dependent cyclin D1 gene expression regulated by 
cadherin- and integrin-mediated adhesion. J Cell Sci. 2008; 
121:226-233.
34. Johnson E, Seachrist DD, DeLeon-Rodriguez CM, Lozada 
KL, Miedler J, Abdul-Karim FW and Keri RA. HER2/
ErbB2-induced breast cancer cell migration and invasion 
require p120 catenin activation of Rac1 and Cdc42. J Biol 
Chem. 2010; 285:29491-29501.
35. Moasser MM. The oncogene HER2; Its signaling and 
transforming functions and its role in human cancer 
pathogenesis. Oncogene. 2007; 26:6469-6487.
36. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta 
D, Ratzkin BJ, Seger R, Hynes NE and Yarden Y. ErbB-2 
is a common auxiliary subunit of NDF and EGF receptors: 
implications for breast cancer. Embo J. 1996; 15:254-264.
37. Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra 
M, Candido S, Nicoletti F, Polesel J, Maestro R, D’Assoro 
A, Drobot L, Rakus D, Gizak A, Laidler P, Dulinska-
Litewka J, Basecke J, et al. Deregulation of the EGFR/
PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: 
possibilities for therapeutic intervention. Oncotarget. 2014; 
5:4603-4650.
38. Avivar-Valderas A, Wen HC and Aguirre-Ghiso JA. 
Stress signaling and the shaping of the mammary tissue in 
development and cancer. Oncogene. 2014; 33:5483-5490.
39. Zhao Y, Wang Z, Jiang Y and Yang C. Inactivation of Rac1 
reduces Trastuzumab resistance in PTEN deficient and 
insulin-like growth factor I receptor overexpressing human 
breast cancer SKBR3 cells. Cancer Lett. 2011; 313:54-63.
40. Wetterskog D, Shiu KK, Chong I, Meijer T, Mackay A, 
Lambros M, Cunningham D, Reis-Filho JS, Lord CJ 
and Ashworth A. Identification of novel determinants 
Oncotarget19www.impactjournals.com/oncotarget
of resistance to lapatinib in ERBB2-amplified cancers. 
Oncogene. 2014; 33:966-976.
41. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies 
J, Li Q and Szallasi Z. An online survival analysis tool to 
rapidly assess the effect of 22,277 genes on breast cancer 
prognosis using microarray data of 1,809 patients. Breast 
Cancer Res Treat. 2010; 123:725-731.
42. Yagi S, Matsuda M and Kiyokawa E. Chimaerin suppresses 
Rac1 activation at the apical membrane to maintain the cyst 
structure. PLoS one. 2012; 7:e52258.
43. Takaishi K, Sasaki T, Kotani H, Nishioka H and Takai 
Y. Regulation of cell-cell adhesion by rac and rho 
small G proteins in MDCK cells. J Cell Biol. 1997; 
139:1047-1059.
44. Lecuit T and Lenne P-F. Cell surface mechanics and the 
control of cell shape, tissue patterns and morphogenesis. 
Nat Rev Mol Cell Biol. 2007; 8:633-644.
45. Graff JR, Gabrielson E, Fujii H, Baylin SB and Herman 
JG. Methylation patterns of the E-cadherin 5′ CpG island 
are unstable and reflect the dynamic, heterogeneous loss of 
E-cadherin expression during metastatic progression. J Biol 
Chem. 2000; 275:2727-2732.
46. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD 
and Muller WJ. Expression of the neu protooncogene in the 
mammary epithelium of transgenic mice induces metastatic 
disease. Proc Nat Acad Sci USA. 1992; 89:10578-10582.
47. Shin D-H, Park J-H, Lee J-Y, Won H-Y, Jang K-S, 
Min K-W, Jang S-H, Woo J-K, Oh SH and Kong G. 
Overexpression of Id1 in transgenic mice promotes 
mammary basal stem cell activity and breast tumorigenesis. 
Oncotarget. 2015; 6:17276-17290.
48. Elston CW and Ellis IO. Pathological prognostic factors in 
breast cancer. I. The value of histological grade in breast 
cancer: experience from a large study with long-term 
follow-up. Histopathology. 1991; 19:403-410.
49. Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma 
E, Martínez-Torteya A, Chacolla-Huaringa R, Rodriguez-
Barrientos A, Tamez-Peña JG and Treviño V. SurvExpress: 
an online biomarker validation tool and database for cancer 
gene expression data using survival analysis. PLoS one. 
2013; 8:e74250.
